|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
WednesdayGeneric Glatiramer, Cannabis Product Advance for MSA lower-cost version of one of the mainstays of first-line multiple sclerosis treatment appears poised to win marketing approval on the basis of pivotal trial results, and the marijuana derivative known as Sativex was, for the first time, shown to improve an objective measure of spasticity in a randomized trial. The studies were presented recently at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), held jointly this year with its North American counterpart, ACTRIMS. Read more ยป Labels: Medical Marijuana, sativex |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||